Find and Pitch Jounalists, Get Your Story Covered

Tags: cabozantinib atezolizumab prostate cancer docetaxel castrate-resistant prostate cancer

	Profile	Recent Articles on Subject
1	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Avutometinib Plus Defactinib Moves One Step Closer to Approval for Treatment of Ovarian Cancer - 26 days ago SABCS 2024: Camizestrant Shows Promise in Combination with Ribociclib for Advanced Breast Cancer - about 2 months ago SABCS 2024: Combination of Elacestrant and Abemaciclib Shows Promising Progression-Free Survival in ER+/HER2- Advanced Breast Cancer - about 2 months ago CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC - 2 months ago New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer - 6 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 10 months ago
2	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	EC approves Rybrevant with Lazcluze for advanced lung cancer - 30 days ago
3	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Testing Elacestrant With Other Targeted Drugs for Metastatic Breast Cancer - about 1 month ago Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 7 months ago Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 7 months ago Cabozantinib Plus Atezolizumab Improves PFS in Metastatic CRPC - 11 months ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - about 1 year ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - about 1 year ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - about 1 year ago
4	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	New First-Line Option for Advanced ALK-Positive Lung Cancer - about 1 month ago FDA Approves Zanidatamab for Biliary Tract Cancer - 2 months ago Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer - 5 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 5 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 5 months ago Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - about 1 year ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - about 1 year ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - about 1 year ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - about 1 year ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - about 1 year ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - about 1 year ago FDA OKs New Option for Advanced ROS1-Positive Lung Cancer - about 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago
5	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 5 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 5 months ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - 11 months ago FDA Approves Rybrevant as First-Line Treatment for NSCLC - 11 months ago FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC - 12 months ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - 12 months ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - about 1 year ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - about 1 year ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - about 1 year ago FDA Approves Repotrectinib for Treatment of ROS1-Positive NSCLC - about 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - about 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - over 1 year ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - over 1 year ago
6	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	MHRA approves Astellas’ Vyloy combination for gastric cancer - 5 months ago
7	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 8 months ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 11 months ago Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial - about 1 year ago New Oral Drug Approved for Metastatic Colorectal Cancer - about 1 year ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - over 1 year ago
8	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 12 months ago Phase 3 Results Show First-Line Amivantamab-vmjw Plus Chemotherapy Prolongs Survival In Patients With Advanced or Metastatic NSCLC - about 1 year ago
9	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies - about 1 year ago Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer - about 1 year ago Abemaciclib, Nonsteroidal Aromatase Inhibitor Extends Overall Survival for Patients With HR+, HER2- Advanced Breast Cancer - about 1 year ago New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations - about 1 year ago
10	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	FDA Issues Complete Response Letter to Astellas for Zolbetuximab BLA for GEJ Adenocarcinoma - about 1 year ago FDA Fast Tracks eFFECTOR Therapeutics' Zotatifin Combo for ER+/HER2– Breast Cancer - about 1 year ago FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer - about 1 year ago FDA Approves New Chemotherapy-Free Treatment Option for Metastatic Colorectal Cancer - about 1 year ago

Journalists covering cabozantinib